BIIB Rega marang bathi mangsa ngarep Biogen
The forward P/E ratio of Biogen Inc. (BIIB) reflects the asset's valuation dynamics, with the current parameter standing at 15.70. Sales of Leqembi and Skyclarys are supporting growth, although cash flow volatility is increasing due to an aging drug portfolio. Strict environmental controls and the achieved carbon neutrality of production processes further complement the business's stability.
Biogen Idec (BIIB) - rincian metrik lan laporan keuangan
- kuotasi lan prakiraan analis:
- data kapitalisasi pasar:
- data ekuitas miturut neraca:
- data tingkat utang lan likuiditas finansial:
Utang marang Ekuitas Biogen Inc.|BIIB - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Biogen Inc.|BIIB - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Biogen Inc|BIIB - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Biogen|Rasio cepet biogen.com
- statistik bathi lan rasio pasar:
BIIB - Penghasilan resik|Bathi mangsa ngarep Biogen Inc.|BIIB - Periode bali modal bisnis|Pangali Forward P/E Biogen Corp|BIIB - Rasio rega marang bathi tumrap wutah|Pangali EV/EBITDA Biogen Inc|BIIB - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Biogen|BIIB - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan biogen.com|BIIB - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Biogen Inc.
Pambiji fundamental:Biogen
To distinguish between stable assets and speculative instruments, capital requires precise yield forecasting. Biogen Inc. (BIIB) demonstrates high resilience, as demand for its unique gene therapy remains independent of economic cycles. Analyzing this chart of the company's forward P/E ratio, an investor can see the relationship between the current price and expected earnings. This calculation reveals hidden business degradation or confirms its fundamental attractiveness. Low indicator values signal that the stable biopharmaceutical business is undervalued.
Pesaing utama
Pangali Forward P/E NBIX|Kapitalisasi marang proyeksi bathi Regencell Bioscience Ltd|Rega marang bathi mangsa ngarep Axsome Therapeutics Inc AXSM|ACADIA Corp (ACAD) - Rasio prakiraan rega marang bathi|Xenon Pharmaceuticals - Pangali Forward P/E|Pangali forward rega marang bathi vikingtherapeutics.com (VKTX)|SUPN: Pangali Forward P/E|Rasio prakiraan rega marang bathi Catalyst Pharma (CPRX)|Rega marang bathi mangsa ngarep Denali Therapeutics Inc|Rasio rega marang bathi mangsa ngarep HRMY (Harmony Corp)|Prakiraan rega marang bathi BHVN (Biohaven Ltd.)|AMLX (amylyx.com) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E TRVI (Trevi Therapeutics, Inc.)|Kapitalisasi marang proyeksi bathi Praxis Precision Medicines Inc (PRAX)|AVXL - Rega marang bathi mangsa ngarep|CBLL (CeriBell EEG) - Rasio rega marang bathi mangsa ngarep|PRTA: Pangali Forward P/E|Prakiraan rega marang bathi Alector|Prakiraan rega marang bathi ANNX|Omeros Corp. (OMER) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E NGNE|Rega marang bathi mangsa ngarep ACIU (AC Immune Inc)|Pangali Forward P/E VYGR (Voyager Therapeutics)|Kapitalisasi marang proyeksi bathi neumoratx.com (NMRA)|Scilex - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi Tevogen Bio Holdings Inc. TVGN|ACOG: Pangali Forward P/E|CGTX (Cognition Therapeutics Inc.) - Rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Inhibikase Therapeutics|Rasio rega marang bathi mangsa ngarep SAVA (cassavasciences.com)|Pangali Forward P/E ASRT|COYA - Rasio prakiraan rega marang bathi|Vistagen - Prakiraan rega marang bathi|Pangali Forward P/E Ovid Therapeutics Inc OVID|ABOS - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi CRVO (cervomed.com)|alteritytherapeutics.com (ATHE) - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi Clene (CLNN)|PEPG (PepGen Inc) - Pangali Forward P/E|Rega marang bathi mangsa ngarep JUNS|Pangali Forward P/E RLMD|Kapitalisasi marang proyeksi bathi annovisbio.com|Rega marang bathi mangsa ngarep Grace Therapeutics GRCE|Firefly Neuroscience, Inc. (AIFF) - Rasio prakiraan rega marang bathi|ANEW Medical, Inc. - Pangali Forward P/E|Pangali forward rega marang bathi NeuroSense Therapeutics (NRSN)|RVPH: Pangali Forward P/E|Rasio prakiraan rega marang bathi MetaVia (MTVA)|Rega marang bathi mangsa ngarep NeurAxis|Rasio rega marang bathi mangsa ngarep HSDT (Helius Medical Technologies Inc.)|Prakiraan rega marang bathi PASG (Passage Bio, Inc.)|NEUP (bionomics.com.au) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E NERV (Minerva Neurosciences)|Kapitalisasi marang proyeksi bathi athira.com (ATHA)|ADXN - Rega marang bathi mangsa ngarep|ALZN (Alzamend Neuro, Inc.) - Rasio rega marang bathi mangsa ngarep|CYCN: Pangali Forward P/E|Prakiraan rega marang bathi Protagenic Therapeutics, Inc.|Prakiraan rega marang bathi KTTA|Cortigent Medical (CRGT) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E ATXI|Rega marang bathi mangsa ngarep BCLI (Brainstorm Cell Therapeutics Inc.)|Pangali Forward P/E CARA (Cara Therapeutics, Inc)|Kapitalisasi marang proyeksi bathi Chromocell (CHRO)|Eliem - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi Intra-Cellular Therapies ITCI|LBPH: Pangali Forward P/E|MRNS (Marinus Pharmaceuticals Inc) - Rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep NKGen|Rasio rega marang bathi mangsa ngarep NRBO (NeuroBo Pharma)|Pangali Forward P/E SAGE|SNPX - Rasio prakiraan rega marang bathi|Trevena - Prakiraan rega marang bathi|Pangali Forward P/E Vigil Neuroscience Inc. VIGL|WENA - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi CERE (Cerevel Corp)
